Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Centessa Pharmaceuticals ( (CNTA) ) has shared an announcement.
On June 24, 2026, Centessa Pharmaceuticals fully repaid and terminated its loan and security agreement with Oxford Finance and other lenders, as part of its acquisition by Eli Lilly’s subsidiary LDH XV Corporation. That same day, following a U.K. court-sanctioned scheme of arrangement first approved on June 22, 2026, Lilly acquired all outstanding Centessa shares for $38 in cash per share plus non-transferable contingent value rights of up to $9 per share, covering ordinary stock, options and restricted stock units under company equity plans.
At the effective time of the deal on June 24, 2026, Centessa became a wholly owned Lilly subsidiary, its shareholders lost all shareholder rights in exchange for the transaction consideration, and the company moved to delist and deregister its ADSs from Nasdaq, ending its public-reporting status. The acquisition triggered a broad management and board overhaul, with Centessa’s senior executives and directors departing, two new directors appointed by the buyer, and the termination of an at-the-market equity offering program, underscoring Centessa’s transition from an independent, market-listed biotech to a fully integrated unit within Lilly’s corporate structure.
The most recent analyst rating on (CNTA) stock is a Hold
with a $42.00 price target.
To see the full list of analyst forecasts on Centessa Pharmaceuticals stock,
see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Neutral.
The score is held back primarily by weak financial performance (no TTM revenue, large losses, and substantial cash burn). Offsetting this are meaningful positive corporate events related to the Eli Lilly acquisition process and moderately constructive technicals, while valuation metrics are unfavorable due to ongoing losses and no dividend signal.
To see Spark’s full report on CNTA stock,
click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals is a U.K.-registered biopharmaceutical company focused on developing innovative therapeutics through a portfolio of subsidiary programs. Its operations span discovery and development of novel drug candidates, with its shares previously traded on Nasdaq via American Depositary Shares, giving it access to U.S. capital markets and global healthcare investors.
Average Trading Volume: 2,931,594
Technical Sentiment Signal: Buy
Current Market Cap: $6.22B
For a thorough assessment of CNTA stock, go to TipRanks’ Stock Analysis page.